Characteristics and Clinical Outcomes of BRCA Germline Mutation Carriers with Advanced Breast Cancer Treated with PARP (Poly ADP-Ribose Polymerase) Inhibitors: A Single-Institution Experience
Authors:
- Fatma Nihan Akkoc MustafayevFMFatma Nihan Akkoc Mustafayev
- Elena FountzilasEFElena Fountzilas
- Mark F. MunsellMMMark F. Munsell
- Rachel M. LaymanRLRachel M. Layman
- Clinton YamCYClinton Yam
- Angelica M. GutierrezAGAngelica M. Gutierrez
- Constance T. AlbarracinCAConstance T. Albarracin
- Zamal AhmedZamal Ahmed
- Katharina SchlacherKSKatharina Schlacher
- John A. TainerJohn A. Tainer
- Banu K. ArunBABanu K. Arun
Open Access
Abstract
Background/Objectives: Several trials have highlighted the importance of PARP inhibitors (PARPi) in the treatment of BRCA-associated breast cancers (BC), initiating changes in practice. However, data on the real-life outcomes of PARPi therapy is limited. In this study, we characterized the clinical characteristics and outcomes of patients with advanced BC and germline BRCA pathogenic variants (PVs) who received PARPi therapy. Methods: We conducted a retrospective single-institution cohort study of patients with advanced BC and germline BRCA1/2 PVs treated with PARPi. Outcomes included objective response rate (ORR), progression-free survival (PFS), and overall survival (OS). Survival was estimated using Kaplan–Meier methods, and prognostic factors were evaluated using Cox regression analysis. Results: Of the 107 patients treated with PARPi, 48 (44.9%) and 59 (55.1%) had BRCA1 and BRCA2 PVs, respectively. Ninety-seven patients (90.7%) had invasive ductal carcinoma and 42 (39.3%) had triple-negative BC. Nineteen (17.8%) patients had de novo metastatic BC. Sixty-two (57.9%) patients received at least one line of systemic therapy before PARPi; 24 (22.4%) patients received prior platinum. ORR was 62.6%, and the median duration of response (DoR) was 7 months (range, 2.1–96.2). The median PFS was 9 months (95% CI, 6.9–10.5) and median OS was 25.8 months (95% CI, 18.7–31.5). In multivariable models for PFS, bone metastases (HR = 2.25; 95% CI, 1.40–3.61; p = 0.0008) and lung metastases (HR = 2.40; 95% CI, 1.45–3.98; p = 0.0007) were independently associated with increased risk of progression or death. In multivariable models for OS, brain metastases (HR = 3.54; 95% CI, 1.59–7.90; p = 0.0020), bone metastases (HR = 2.22; 95% CI, 1.27–3.88; p = 0.0050), and lung metastases (HR = 2.38; 95% CI, 1.38–4.11; p = 0.0018), were independently associated with increased risk of death. Conclusions: The clinical outcomes of our real-world patients are similar to those reported in previous clinical trials. In addition, metastatic site distribution was independently prognostic for survival outcomes and may support baseline risk stratification at the time of PARPi initiation. Further studies of predictive markers of response and resistance, as well as sequencing with platinums and combinations with other targeted agents, are needed to optimize the benefits of PARPi in this patient population.Keywords
Funding Information
- Cancer Center Support Grant (P30CA016672)
- Cancer Prevention and Research Institute of Texas (RP180813)
This publication has 32 references indexed in Scilit:
- Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCYBreast Cancer Research and Treatment, 2023
- Olaparib efficacy in patients with germline BRCA ‐mutated, HER2 ‐negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trialInternational Journal of Cancer, 2023
- OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancerEuropean Journal of Cancer, 2023
- Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trialAnnals of Oncology, 2020
- Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet Oncology, 2020
- BMI is an independent prognostic factor for late outcome in patients diagnosed with early breast cancer: A landmark survival analysisThe Breast, 2019
- Hereditary breast cancer; Genetic penetrance and current status with BRCAJournal of Cellular Physiology, 2018
- Overweight, Obesity, and Postmenopausal Invasive Breast Cancer RiskJAMA Oncology, 2015
- Cancer Susceptibility and the Functions of BRCA1 and BRCA2Cell, 2002
- Importance of events per independent variable in proportional hazards regression analysis II. Accuracy and precision of regression estimatesJournal of Clinical Epidemiology, 1995